End-to-end manufacturing refers to the integrated provision of all services required to take a biopharmaceutical product from early development through to commercial production within a single CDMO partner. It encompasses process development, analytical development, GMP manufacturing, quality control, regulatory support, and technology transfer, offering sponsors a streamlined, cost-efficient, and risk-reduced path from preclinical to commercial supply.
